Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.

Published

Conference Paper

Full Text

Published version (via Digital Object Identifier)

Duke Authors

Cited Authors

Desjardins, A; Sampson, JH; Peters, KB; Vlahovic, G; Randazzo, D; Threatt, S; Herndon, JE; Boulton, S; Lally-Goss, D; McSherry, F; Lipp, ES; Friedman, AH; Friedman, HS; Bigner, DD; Gromeier, M

Published Date

May 20, 2016

Published In

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Volume / Issue

34 / 15_suppl

Start / End Page

2061 - 2061

Published By

American Society of Clinical Oncology (ASCO)

Electronic International Standard Serial Number (EISSN)

1527-7755

International Standard Serial Number (ISSN)

0732-183X

Digital Object Identifier (DOI)

10.1200/jco.2016.34.15_suppl.2061